174 related articles for article (PubMed ID: 24842953)
1. Prostate tumor growth is impaired by CtBP1 depletion in high-fat diet-fed mice.
Moiola CP; De Luca P; Zalazar F; Cotignola J; Rodríguez-Seguí SA; Gardner K; Meiss R; Vallecorsa P; Pignataro O; Mazza O; Vazquez ES; De Siervi A
Clin Cancer Res; 2014 Aug; 20(15):4086-95. PubMed ID: 24842953
[TBL] [Abstract][Full Text] [Related]
2. CTBP1 depletion on prostate tumors deregulates miRNA/mRNA expression and impairs cancer progression in metabolic syndrome mice.
Dalton GN; Massillo C; Scalise GD; Duca R; Porretti J; Farré PL; Gardner K; Paez A; Gueron G; De Luca P; De Siervi A
Cell Death Dis; 2019 Apr; 10(4):299. PubMed ID: 30931931
[TBL] [Abstract][Full Text] [Related]
3. Role of transcriptional corepressor CtBP1 in prostate cancer progression.
Wang R; Asangani IA; Chakravarthi BV; Ateeq B; Lonigro RJ; Cao Q; Mani RS; Camacho DF; McGregor N; Schumann TE; Jing X; Menawat R; Tomlins SA; Zheng H; Otte AP; Mehra R; Siddiqui J; Dhanasekaran SM; Nyati MK; Pienta KJ; Palanisamy N; Kunju LP; Rubin MA; Chinnaiyan AM; Varambally S
Neoplasia; 2012 Oct; 14(10):905-14. PubMed ID: 23097625
[TBL] [Abstract][Full Text] [Related]
4. CTBP1/CYP19A1/estradiol axis together with adipose tissue impacts over prostate cancer growth associated to metabolic syndrome.
Massillo C; Dalton GN; Porretti J; Scalise GD; Farré PL; Piccioni F; Secchiari F; Pascuali N; Clyne C; Gardner K; De Luca P; De Siervi A
Int J Cancer; 2019 Mar; 144(5):1115-1127. PubMed ID: 30152543
[TBL] [Abstract][Full Text] [Related]
5. Fanconi anemia proteins interact with CtBP1 and modulate the expression of the Wnt antagonist Dickkopf-1.
Huard CC; Tremblay CS; Helsper K; Delisle MC; Schindler D; Lévesque G; Carreau M
Blood; 2013 Mar; 121(10):1729-39. PubMed ID: 23303816
[TBL] [Abstract][Full Text] [Related]
6. The low-abundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer.
Bizama C; Benavente F; Salvatierra E; Gutiérrez-Moraga A; Espinoza JA; Fernández EA; Roa I; Mazzolini G; Sagredo EA; Gidekel M; Podhajcer OL
Int J Cancer; 2014 Feb; 134(4):755-64. PubMed ID: 23907728
[TBL] [Abstract][Full Text] [Related]
7. CtBP1 associates metabolic syndrome and breast carcinogenesis targeting multiple miRNAs.
De Luca P; Dalton GN; Scalise GD; Moiola CP; Porretti J; Massillo C; Kordon E; Gardner K; Zalazar F; Flumian C; Todaro L; Vazquez ES; Meiss R; De Siervi A
Oncotarget; 2016 Apr; 7(14):18798-811. PubMed ID: 26933806
[TBL] [Abstract][Full Text] [Related]
8. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
[TBL] [Abstract][Full Text] [Related]
9. CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease.
Porretti J; Dalton GN; Massillo C; Scalise GD; Farré PL; Elble R; Gerez EN; Accialini P; Cabanillas AM; Gardner K; De Luca P; De Siervi A
Int J Cancer; 2018 Aug; 143(4):897-906. PubMed ID: 29536528
[TBL] [Abstract][Full Text] [Related]
10. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
[TBL] [Abstract][Full Text] [Related]
11. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
12. Lycopene metabolite, apo-10'-lycopenoic acid, inhibits diethylnitrosamine-initiated, high fat diet-promoted hepatic inflammation and tumorigenesis in mice.
Ip BC; Hu KQ; Liu C; Smith DE; Obin MS; Ausman LM; Wang XD
Cancer Prev Res (Phila); 2013 Dec; 6(12):1304-16. PubMed ID: 24085778
[TBL] [Abstract][Full Text] [Related]
13. Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer.
Lam HM; Ouyang B; Chen J; Ying J; Wang J; Wu CL; Jia L; Medvedovic M; Vessella RL; Ho SM
Endocr Relat Cancer; 2014; 21(6):903-14. PubMed ID: 25287069
[TBL] [Abstract][Full Text] [Related]
14. CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells.
Deng Y; Guo W; Xu N; Li F; Li J
Mol Carcinog; 2020 May; 59(5):512-519. PubMed ID: 32124501
[TBL] [Abstract][Full Text] [Related]
15. Metformin Reduces Prostate Tumor Growth, in a Diet-Dependent Manner, by Modulating Multiple Signaling Pathways.
Sarmento-Cabral A; L-López F; Gahete MD; Castaño JP; Luque RM
Mol Cancer Res; 2017 Jul; 15(7):862-874. PubMed ID: 28385910
[TBL] [Abstract][Full Text] [Related]
16. High-fat diet-induced obesity increases lymphangiogenesis and lymph node metastasis in the B16F10 melanoma allograft model: roles of adipocytes and M2-macrophages.
Jung JI; Cho HJ; Jung YJ; Kwon SH; Her S; Choi SS; Shin SH; Lee KW; Park JH
Int J Cancer; 2015 Jan; 136(2):258-70. PubMed ID: 24844408
[TBL] [Abstract][Full Text] [Related]
17. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
[TBL] [Abstract][Full Text] [Related]
18. GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis.
Kalakonda S; Nallar SC; Lindner DJ; Sun P; Lorenz RR; Lamarre E; Reddy SP; Kalvakolanu DV
Oncogene; 2014 Jun; 33(24):3195-204. PubMed ID: 23851499
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cells.
Filograna A; De Tito S; Monte ML; Oliva R; Bruzzese F; Roca MS; Zannetti A; Greco A; Spano D; Ayala I; Liberti A; Petraccone L; Dathan N; Catara G; Schembri L; Colanzi A; Budillon A; Beccari AR; Del Vecchio P; Luini A; Corda D; Valente C
J Exp Clin Cancer Res; 2024 May; 43(1):137. PubMed ID: 38711119
[TBL] [Abstract][Full Text] [Related]
20. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
